Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
AbbVie Unusual Options Activity
The "Most-Favored-Nation Pricing" policy for Trump Medicine has been issued: benchmarked against developed countries, complete the Quote within 30 days.
① This policy aims to align prescription drug pricing in the USA with that of "Other developed countries". Trump has requested that the Quote be completed within 30 days; ② The scope of affected Pharmaceuticals is still unclear, and the White House has stated that the government will pay special attention to drugs that have the "largest price differences and highest spending"; ③ Trump had implemented a similar policy before the end of his last term, but it was blocked by the courts and ultimately fell through.
Congressional Trading Report: Rep. Jared Moskowitz Bought Over $27K In AbbVie Stock
Innovation, Pharma Profits Won't Suffer Under Trump Prescription Drug EO - White House
Trump's Drug Price Cuts: Will They Work?
Analyst Expectations For Insmed's Future
Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress
United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.
Trump Vows to Cut Drug Prices in the U.S. by up to 80%
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
U.S. Pharma Imports Soar in March as Drugmakers Look to Get Ahead of Potential Tariffs
Insmed Analyst Ratings
10 Health Care Stocks With Whale Alerts In Today's Session
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Recent Report Shows That Rep. Jefferson Shreve Bought Up to $4.75M Worth of Apple Stock
8 Analysts Have This To Say About Natera
Natera Analyst Ratings
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Natera Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance Above Estimates.